Amneal Pharmaceuticals, Inc.
AMRX
$1.31
$0.043.15%
| Weiss Ratings | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | D | |||
| Rating Factors | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.17 | |||
| Price History | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.39% | |||
| 30-Day Total Return | -46.96% | |||
| 60-Day Total Return | -34.17% | |||
| 90-Day Total Return | -41.26% | |||
| Year to Date Total Return | -37.91% | |||
| 1-Year Total Return | -68.96% | |||
| 2-Year Total Return | -80.68% | |||
| 3-Year Total Return | -57.33% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -72.39% | |||
| 52-Week Low % Change | 2.42% | |||
| Price | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.60 | |||
| 52-Week Low Price | $1.24 | |||
| 52-Week Low Price (Date) | Mar 28, 2023 | |||
| 52-Week High Price (Date) | Apr 08, 2022 | |||
| Valuation | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | $194.71M | |||
| Enterprise Value | 2.92B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.87 | |||
| Earnings Per Share Growth | -1,435.49% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.09 | |||
| Price/Book (Q) | 0.64 | |||
| Enterprise Value/Revenue (TTM) | 1.32 | |||
| Price | $1.31 | |||
| Enterprise Value/EBITDA (TTM) | 6.64 | |||
| Enterprise Value/EBIT | 14.61 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 151.476M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 908 947 3120 | |||
| Address | 400 Crossing Boulevard Bridgewater, NJ 08807 | |||
| Website | amneal.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 9.04% | |||
| Profit Margin | -5.87% | |||
| Management Effectiveness | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.23% | |||
| Return on Equity | -- | |||
| Income Statement | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | $2.21B | |||
| Total Revenue (TTM) | $2.21B | |||
| Revenue Per Share | $14.60 | |||
| Gross Profit (TTM) | $791.46M | |||
| EBITDA (TTM) | $440.21M | |||
| EBIT (TTM) | $200.03M | |||
| Net Income (TTM) | -$129.99M | |||
| Net Income Avl. to Common (TTM) | -$129.99M | |||
| Total Revenue Growth (Q YOY) | 13.57% | |||
| Earnings Growth (Q YOY) | 71.37% | |||
| EPS Diluted (TTM) | -$0.87 | |||
| EPS Diluted Growth (Q YOY) | 27.63% | |||
| Balance Sheet | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | $27.80M | |||
| Cash Per Share (Q) | $0.18 | |||
| Total Current Assets (Q) | $1.41B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | $208.93M | |||
| Current Ratio (Q) | 1.875 | |||
| Book Value Per Share (Q) | $1.97 | |||
| Total Assets (Q) | $3.80B | |||
| Total Current Liabilities (Q) | $752.80M | |||
| Total Debt (Q) | $2.85B | |||
| Total Liabilities (Q) | $3.59B | |||
| Total Common Equity (Q) | $298.42M | |||
| Cash Flow | AMRX - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -$174.31M | |||
| Cash from Financing (TTM) | -$106.62M | |||
| Net Change in Cash (TTM) | -$221.51M | |||
| Levered Free Cash Flow (TTM) | $104.18M | |||
| Cash from Operations (TTM) | $65.10M | |||
